Cicletanine

Cicletanine
Clinical data
AHFS/Drugs.comInternational Drug Names
Routes of
administration		Oral
ATC code
Pharmacokinetic data
Protein binding99.6% for (-)cicletanine isomer; 87.5% for (+)cicletanine isomer
Elimination half-life5.7 h. Also: Tmax = 0.750 hours. Plasma AUCinf = 29.0 μg·hr/mL. Cmax = 6.18 μg/mL. All figures are for a single oral dose of 150 mg.
Identifiers
  • 3-(4-Chlorophenyl)-6-methyl-1,3-dihydrofuro[3,4-c]pyridin-7-ol
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.158.583 Edit this at Wikidata
Chemical and physical data
FormulaC14H12ClNO2
Molar mass261.71 g·mol−1
3D model (JSmol)
  • Clc1ccc(cc1)C3OCc2c3cnc(c2O)C
  • InChI=1S/C14H12ClNO2/c1-8-13(17)12-7-18-14(11(12)6-16-8)9-2-4-10(15)5-3-9/h2-6,14,17H,7H2,1H3 checkY
  • Key:CVKNDPRBJVBDSS-UHFFFAOYSA-N checkY
  (verify)

Cicletanine is a furopyridine compound approved in France for the treatment of hypertension.[1] The drug is most commonly known as a diuretic drug, but has a broader range of cardiovascular and metabolic activity characterized extensively in the literature (see "Mechanism" below).

Cicletanine was originated and in 1986 launched in France by Paris-based Ipsen, who in 2005 licensed marketing rights in France to Milan-based Recordati for several years (at least until 2010). Ipsen and Recordati both marketed cicletanine under the trade name Tenstaten. The drug is no longer manufactured nor sold by IPSEN; it is currently marketed in France by three generics manufacturers: Viatris, Biogaran, and Teva Pharmaceuticals.

Cicletanine has been shown to be differentially effective in salt-sensitive hypertension.[2]

  1. ^ Sassard J (1992). Genetic Hypertension. John Libbey Eurotext. ISBN 978-0-86196-313-3.
  2. ^ Bagrov AY, Dmitrieva RI, Dorofeeva NA, Fedorova OV, Lopatin DA, Lakatta EG, Droy-Lefaix MT (February 2000). "Cicletanine reverses vasoconstriction induced by the endogenous sodium pump ligand, marinobufagenin, via a protein kinase C dependent mechanism". Journal of Hypertension. 18 (2): 209–215. doi:10.1097/00004872-200018020-00012. PMID 10694190. S2CID 35374482.